Anika Therapeutics (ANIK) Non-Current Assets (2010 - 2026)

Anika Therapeutics (ANIK) has reported Non-Current Assets for 17 consecutive years, with $84.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 4.62% year-over-year to $84.3 million in Q2 2026; TTM through Jun 2026 was $344.9 million, a 4.43% decrease from a year earlier, with the FY2025 full-year figure at $86.9 million, down 2.44% from the prior year.
• Non-Current Assets was $84.3 million for Q2 2026 at Anika Therapeutics, down from $85.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $186.3 million in Q2 2022 and troughed at $84.3 million in Q2 2026.
• A 5-year average of $126.4 million and a median of $106.1 million in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets climbed 1.03% in 2023 and tumbled 44.39% in 2024, its largest moves.
• Over 5 years, Non-Current Assets stood at $179.6 million in 2022, then plunged by 40.24% to $107.3 million in 2023, then retreated by 16.99% to $89.1 million in 2024, then fell by 2.44% to $86.9 million in 2025, then retreated by 3.02% to $84.3 million in 2026.
• The last three Non-Current Assets figures came in at $84.3 million (Q2 2026), $85.8 million (Q1 2026), and $86.9 million (Q4 2025), per Business Quant data.